Teva CFS Book English

Getting it done together Prominent launches at the Kfar Saba site 2004-2010 Product Year Launched Purpose Background Rasagiline 2004 Treating Parkinson’s disease The second innovative drug that Teva developed Also known by the brand name Azilect 100 million tablets are currently manufactured per year and the drug sales amount to around 400 million dollars, thanks to marketing to around 40 countries worldwide. Gabapentin 2004 Anticonvulsant used as a first line treatment for neuropathic pain Risky launch. Fexofenadine 2005 Used to treat allergic rhinitis, hay fever and allergic skin reactions (a new generation drug that does not cause drowsiness) Risky launch. Simvastatin 2006 Treats high cholesterol levels in the blood. Blocks the activity of the enzyme required to make cholesterol in the liver, and consequently the cholesterol levels in the blood decrease. The largest generic launch in history (up to that point) took 4 months of work and in terms of tablets - around half a billion tablets exclusively. Pravastatin 2006 Lowering blood cholesterol levels Sertraline 2006 Anti-anxiety and antidepressant drug Pantoprazole 2007 Used to treat gastric ulcers A huge risky launch (174 batches, 313 million tablets) that was prepared in a mere 8 weeks! Extended release drug. Sales of over a billion dollars in the years following the launch. Amlodipine / Benazepril 2008 Treating hypertension and angina Risky launch. 300 million capsules manufactured in 8 weeks! Venlafaxine ER caps 2010 Anti-anxiety and antidepressant drug The largest generic launch in terms of money - 800 million dollars. A new product in three different dosages. Immense strategic and economic importance for Teva: high complexity from both the technological and operational aspects. The plant produced over 200 million capsules, which were packaged in over 5 million bottles - for a total 131 batches. 53